BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities. The strategic transaction will combine complementary mRNA...

Eli Lilly and Company and SiteOne Therapeutics, , a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne “The global...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Although Vigil has two candidates in...